Want to see STOK full AI Analyst Report?
Stoke Therapeutics (STOK) Income Statement
Stoke Therapeutics Income Statement
Last quarter (Q2 2026), Stoke Therapeutics's total revenue was $9.32M, a decrease of 32.51% from the same quarter last year. In Q2, Stoke Therapeutics's net income was $-61.62M. See Stoke Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 184.42M | $ 36.55M | $ 8.78M | $ 12.40M | $ 0.00 | |
| $ 184.42M | $ 36.55M | $ 8.78M | $ 12.40M | $ 0.00 | |
| $ 205.01M | $ 137.93M | $ 123.55M | $ 116.76M | $ 86.06M | |
| Depreciation and Amortization | $ 1.77M | $ 2.18M | $ 2.47M | $ 1.55M | $ 974.00K |
| $ -5.12M | $ -86.80M | $ -102.23M | $ -99.52M | $ -84.83M | |
| $ -20.59M | $ -101.37M | $ -114.77M | $ -104.36M | $ -86.06M | |
| $ 13.71M | $ 12.39M | $ 10.07M | $ 3.29M | $ 260.00K | |
| $ -6.88M | $ -88.98M | $ -104.70M | $ -101.07M | $ -85.81M | |
| $ -6.88M | $ -88.98M | $ -104.70M | $ -101.07M | $ -85.81M | |
| Per Share Metrics | |||||
| Basic EPS | $ -0.12 | $ -1.65 | $ -2.38 | $ -2.60 | $ -2.34 |
| Diluted EPS | $ -0.12 | $ -1.65 | $ -2.38 | $ -2.60 | $ -2.34 |
| Weighted Average Shares Outstanding | 59.22M | 54.01M | 43.99M | 38.90M | 36.74M |
| Weighted Average Shares Outstanding (Diluted) | 59.22M | 54.01M | 43.99M | 38.90M | 36.74M |
Currency in USD